@Delta4_98: "What would be your target price for $CHTP on a CRL?"
Chelsea Therapeutics' (CHTP) stock price will fall if FDA rejects Northera on March 28; how much depends on what demands the agency places on the company in order to resubmit the drug for approval again.
Best case: If Chelsea only needs to negotiate final labeling for Northera and/or make minor fixes to manufacturing, the stock shouldn't drop too much. I hate making guesses on stock prices but let's say a 20% drop. [This assumes a relatively fast resubmission and a three-month response from FDA.]
Worst case: FDA asks for additional clinical data on Northera, Chelsea shares are more likely to fall 50% or more. Chelsea's market value may not fall as much if the company can use Study 306b results expected in third quarter. If an entirely new clinical trial of Northera is needed, the sell off will be more severe.@BlacknGoldFool: "Can you please remind everyone your take on $KERX? Just want to make sure you get your last bit of hate mail in!" I'm no fan of Keryx Pharmaceuticals (KERX), mainly because I see failure ahead for the phase III study of perifosone in advanced colon cancer. On Monday, Keryx said that the 360th patient death needed to start the final analysis of the perifosine trial is likely to occur in March. If we assume Keryx is using electronic data capture in the trial, top-line results should be available in April, or May at the latest. I won't rehash here the myriad reasons for why I predict perifosine won't work, but please revisit my previous columns on how Keryx runs afoul of the so-called Feuerstein-Ratain Rule governing cancer drug development. @matthewherper, my friend and Forbes drug scribe, asks, "How does Max smell?" To which, @kevinccc interjected, "With his nose. How do you do it?" These days, Max (badly in need of a trip to the groomer) smells a lot like those wet towels you left crumpled in the corner of your room for a few days. That and a lingering essence of skunk, the result of an unfortunate encounter a few weeks ago. He's still the best dog in the world. @HemPaddy: "2012 PDUFA or Adcomm event you strongly believe will be +ve or -ve, that most of the street disagrees with? (not VVUS, CHTP)" I'm having trouble coming up with a contrarian opinion on an FDA drug approval. I was surprised that nearly all of my picks in TheStreet's FDA Drug Approval Contest line up with the consensus view.
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass + 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV